ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Targeting metabolism to overcome cancer drug resistance: A promising therapeutic strategy for diffuse large B cell lymphoma

Pi, Manfei; Kuang, Huixian; Yue, Chunyan; Yang, Qixuan; Wu, Anqin; Li, Yuhua; Assaraf, Yehuda G.; Yang, Dong-Hua*; Wu, Shaojie*南方医科大学
DRUG RESISTANCE UPDATES2022-3DOI: 10.1016/j.drup.2022.100822
24被引4阅读
引用收藏
分享

摘要

Cancer cell metabolism including aerobic glycolysis, amino acid and fatty acid metabolism, has been extensively studied. Metabolic reprogramming is a major hallmark of cancer, which promotes cancer cell proliferation, progression and metastasis, as well as provokes resistance to chemotherapeutic drugs. Several signal transduction pathways, such as BCR, MEK/ERK, Notch, NF-KB and PI3K/AKT/mTOR, regulate tumor metabolism, hence promoting tumor cell growth, proliferation and progression. Therefore, targeting metabolic enzymes, metabolites or their signal transduction pathways may constitute a promising therapeutic strategy to enhance cancer treatment efficacy. Diffuse large B-cell lymphoma (DLBCL) is the most aggressive form of non-Hodgkin lymphoma (NHL), and one-third of DLBCL patients suffer from relapsed/refractory disease after chemotherapy. The mechanisms underlying drug resistance are complex, including target gene mutations, metabolic reprogramming, aberrant signal transduction pathways, enhanced drug efflux via overexpression of multidrug efflux transporters like P-glycoprotein, upregulation of anti-apoptotic proteins, drug sequestration and enhanced DND repair. This review delineates the distinct metabolic reprogramming patterns and the association between metabolism and anticancer drug resistance in DLBCL as well as the emerging strategies to surmount chemoresistance in DLBCL.

学科与关键词

关键词
diffuse large B cell lymphomatumor metabolismcancer drug resistance
相关
加载中…
  • Amino acid metabolism: challenges and opportunities for the therapeutic treatment of leukemia and lymphoma
    Liao, Peiyun; Chang, Ning; Xu, Binyan; Qiu, Yingqi; Wang, Sheng; Zhou, Lijuan; He, Yanjie; Xie, Xiaoling*; Li, Yuhua*Immunology and Cell Biology, 2022, 100(7): 507-528.被引 5
  • Immune microenvironment-related gene mapping predicts immunochemotherapy response and prognosis in diffuse large B-cell lymphoma
    Chen, Wanjun; Liang, Weijie; He, Yongjian; Liu, Chixiang; Chen, Hongtian; Lv, Piao; Yao, Yuan; Zhou, Huayou*MEDICAL ONCOLOGY, 2022, 39(4): 44.被引 5
  • Lenalidomide in Diffuse Large B-Cell Lymphoma
    Catherine Thieblemont; Marie-Hélène Delfau-Larue; Bertrand CoiffierAdvances in Hematology, 2012, 2012: 1-8.
查看全部 →

发表信息

论文状态
公开发表
期刊
DRUG RESISTANCE UPDATES
发表日期
2022-03
卷期
第 61 卷
页码
100822
DOI
10.1016/j.drup.2022.100822
语言
ENGLISH
期刊等级
1区
成果收录
SCIE

作者

  • P

    Pi, Manfei (第一作者)

    southern med univ

  • K

    Kuang, Huixian

    southern med univ

查看全部 9 位作者收起作者
  • Y

    Yue, Chunyan

    southern med univ

  • Y

    Yang, Qixuan

    southern med univ

  • W

    Wu, Anqin

    southern med univ

  • L

    Li, Yuhua

    southern med univ

  • A

    Assaraf, Yehuda G.

  • Y

    Yang, Dong-Hua (通讯)

    new

  • W

    Wu, Shaojie (通讯)

    southern med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417